F. Hepp
- Cancer Research top 2%
- Breast Cancer Treatment Studies 4
- Oncology top 2%
- Cancer Cells and Metastasis 8
- HER2/EGFR in Cancer Research 3
- Pathology and Forensic Medicine top 10%
- Breast Lesions and Carcinomas 1
-
- Sarcoma Diagnosis and Treatment 3
- Metastasis and carcinoma case studies 2
- Lung Cancer Treatments and Mutations 2
- Biotechnology top 10%
-
- Monoclonal and Polyclonal Antibodies Research 2
F. Hepp
14 papers receiving 1.6k citations
Hit Papers
Peers
Comparison fields: 5 of 75
- Cancer Research 830
- Oncology 1.3k
- Pathology and Forensic Medicine 216
- Pulmonary and Respiratory Medicine 356
- Biotechnology 58
Countries citing papers authored by F. Hepp
This map shows the geographic impact of F. Hepp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Hepp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Hepp more than expected).
Fields of papers citing papers by F. Hepp
This network shows the impact of papers produced by F. Hepp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Hepp. The network helps show where F. Hepp may publish in the future.
Co-authorship network
The 25 scholars most cited alongside F. Hepp, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2003 | 21 | |
| 2 | [Incidence and prognostic significance of disseminated tumor cells in patients with cervical cancer]. | 2002 | 1 |
| 3 | 2001 | 62 | |
| 4 | 2001 | 96 | |
| 5 | 2001 | 117 | |
| 6 | 2001 | 61 | |
| 7 | 2000 | 56 | |
| 8 | Cytokeratin-Positive Cells in the Bone Marrow and Survival of Patients with Stage I, II, or III Breast Cancerbreakdown → | 2000 | 726 |
| 9 | 2000 | 315 | |
| 10 | 1999 | 93 | |
| 11 | 1999 | 1 | |
| 12 | 1999 | 1 | |
| 13 | Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow. | 1999 | 109 |
| 14 | Potential clinical relevance of micrometastatic breast cancer | 1998 | 1 |
About F. Hepp
F. Hepp is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 14 papers that have together received 1.7k indexed citations. Recurring topics across this work include Cancer Cells and Metastasis (8 papers), Breast Cancer Treatment Studies (4 papers), Sarcoma Diagnosis and Treatment (3 papers), HER2/EGFR in Cancer Research (3 papers), Metastasis and carcinoma case studies (2 papers), Monoclonal and Polyclonal Antibodies Research (2 papers), Lung Cancer Treatments and Mutations (2 papers) and Breast Lesions and Carcinomas (1 paper). The work is most often cited by research in Cancer Research (830 citations), Oncology (1.3k citations) and Pathology and Forensic Medicine (216 citations). F. Hepp has collaborated with scholars based in Germany, Austria and United States. Frequent co-authors include Stephan Braun, Klaus Pantel, Christina Kentenich, Wolfgang Janni, Harald Sommer, Gert Riethmüller, T. Dimpfl, Peter E. Müller, Günter Schlimok and F Willgeroth. Their work appears in journals such as Cancer, Journal of Clinical Oncology, European Journal of Cancer, New England Journal of Medicine and International Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.